HER2-positive invasive lobular breast cancer in a transgender man: disease-free after multimodality care

Patient Info: Anonymized, transgender man, 70+ | Stage III

Biomarkers: HER2-positive invasive lobular breast cancer, ER/PR negative

Nearly 2 years after diagnosis, he remained disease-free while continuing survivorship care and counseling after discontinuing testosterone therapy.

PubMed CentralRead more →

Stage IV HER2-Positive Non-Small Cell Lung Cancer: Lauren's Patient Story

Patient Info: Lauren, Female, Under 40 | Stage IV

Biomarkers: HER2 mutation

Metastatic Site: Bones/ribs/shoulder; liver

As of September 2025, after about 4 months of targeted therapy, Lauren reported better quality of life, resolved bone pain, improved liver pain, improved liver enzymes, and manageable infusion-week side effects.

The Patient StoryRead more →

Rare soft-tissue sarcoma: surgery and multimodal treatment

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Pathogenic BRIP1 c.1871C>A mutation found in tumor and germline testing; vimentin positive, SMARCB1/SMARCA4 preserved.

Metastatic Site: lung, left hilar lymph node

As of September 2025, she had sustained complete oncologic remission for 36 months after starting olaparib 300 mg twice daily for BRIP1-mutated metastatic undifferentiated pleomorphic sarcoma.

PubMed CentralRead more →

Stage IV BRAF Colorectal Cancer: Jackson's Patient Story

Patient Info: Jackson, Male, Under 40 | Stage IV

Biomarkers: BRAF mutation

Metastatic Site: Liver; peritoneal wall

Jackson had Stage IV BRAF-mutated colon cancer with extensive liver disease and later confirmed peritoneal-wall tumors. His treatment response was strong, with about 90% of liver disease estimated gone, but he remained on active treatment with possible future HIPEC evaluation. As of September 2025, he was responding well but not cancer-free.

The Patient StoryRead more →

Stage IV ALK Lung Cancer: Shauna's Patient Story

Patient Info: Shauna, Female, 50s | Stage IV

Biomarkers: ALK-positive

Metastatic Site: Both lungs

Shauna had Stage IV ALK-positive lung cancer involving both lungs. She was stable for about 5 years on her first TKI, had radiation for limited lung growth, and later switched to a newer TKI with stable scans. She explicitly said she had never had no evidence of disease, so the record should not be labeled NED.

The Patient StoryRead more →

Stage III Ovarian Cancer: Mary's Survivor Story

Patient Info: Mary Catherine Riley, Female, 40s | Stage III

After a 2023 recurrence, Mary achieved a complete response within 1 year on avutometinib and defactinib. She continues the approved combination with quarterly CT scans and monthly labs and has no evidence of disease.

Stage IV Colorectal Cancer: Heather's Patient Story

Patient Info: Heather Candrilli, Female, Under 40 | Stage IV

Metastatic Site: Liver

Heather had Stage IV colon cancer with liver-only metastases. Her scans improved and Signatera became negative, but she still had many liver lesions and was not considered resectable. As of September 2025, she remained on chemotherapy while pursuing living-donor liver transplant evaluation.

The Patient StoryRead more →

Stage IV transverse colon cancer with NTRK fusion: entrectinib response followed by fatal PTTM

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: RAS/BRAF wild type, low TMB. CEA and CA19-9 were elevated before entrectinib and fell with response.

Metastatic Site: peritoneum, greater omentum, pleura,…

He died 7 weeks after hospitalization from pulmonary tumor thrombotic microangiopathy causing severe pulmonary hypertension and right-heart failure, despite biochemical and ascites response to entrectinib.

PubMed CentralRead more →

Stage IV Breast Cancer: Maria's Patient Story

Patient Info: Maria, Female | Stage IV

Metastatic Site: Bone (spine, clavicle, rib, thigh bone, scapula);…

Maria initially had a clean PET scan after chemotherapy, surgery, radiation, and targeted/endocrine therapy, but later developed Stage IV metastatic breast cancer involving multiple bone sites, with lung and cervical-region involvement also described. As of September 2025, she remained on treatment and did not have an available clinical trial option.

The Patient StoryRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Steven's Patient Story

Patient Info: Steven Huff, Male, Under 40 | Stage IV

Biomarkers: ALK-positive

Metastatic Site: Lungs; liver; spine; sacrum; chest lymph nodes;…

Steven had Stage IV ALK-positive NSCLC and responded well to twice-daily oral targeted therapy, with several years of stable scans and a return to teaching and family life. As of September 2025, he remained on active treatment rather than being cancer-free.

The Patient StoryRead more →

Metastatic lung squamous cell carcinoma with T3 vertebral fracture responding to treatment

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: bone (T3 vertebra)

Follow-up imaging at 16 weeks showed sclerosis of the T3 lesion, the patient remained neurologically intact, and brace use could be discontinued.

PubMed CentralRead more →

Stage IV ALK Lung Adenocarcinoma: Allison's Patient Story

Patient Info: Allison, Female, 40s | Stage IV

Biomarkers: ALK-positive fusion; later ALK resistance mutations reported

Metastatic Site: Bone (spine, femur, ribs, shoulder); brain

Allison was living with Stage IV ALK-positive lung cancer and had a strong response to targeted therapy: brain lesions cleared, most PET activity resolved, and the primary tumor shrank to about 1.5 cm. As of August 2025, she remained on second-line targeted therapy.

The Patient StoryRead more →

Breast Cancer: Marissa's Survivor Story

Patient Info: Marissa Coreno, Female, Under 40

Biomarkers: Tumor biomarkers not reported; no apparent genetic predisposition for breast cancer

As of August 2025, Marissa was 31, had no sign of cancer, and remained on estrogen-blocking therapy planned for 10 years after chemotherapy, bilateral mastectomies, reconstruction, radiation, a CDK 4/6 inhibitor pill and a bisphosphonate.

Cleveland ClinicRead more →

Stage IV Breast Cancer: Linda's Patient Story

Patient Info: Linda Norman, Female, 60s | Stage IV

Metastatic Site: Bone: humerus/shoulder region

As of August 2025, Linda was 1 year into treatment for bone-metastatic breast cancer with letrozole, Verzenio, and bone-strengthening infusions; scans showed the tumor had not grown and bone scarring suggested healing.

EGFR-Mutant Stage IV Lung Cancer Treated After Osimertinib-Related Lung Toxicity

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; later EGFR T790M resistance mutation

Metastatic Site: brain, lungs, bones, left adrenal gland, meninges

The latest documented treatment was a lower-dose osimertinib rechallenge with corticosteroids, which reduced the tumor without recurrence of the prior interstitial lung disease.

PubMed CentralRead more →

ROS1-rearranged Stage IV lung adenocarcinoma: sequential targeted therapy and 73-month survival

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: CD74-ROS1 C6:R33 fusion; CTNNB1 p.Thr41Ala; APC p.Glu601fs; acquired ROS1 resistance mutation; mTOR p. mutation; FGFR3 gene amplification

Metastatic Site: contralateral lung nodules, brain, pleura

She died on October 6, 2024, after sequential crizotinib, lorlatinib, and cabozantinib for Stage IV ROS1-rearranged lung adenocarcinoma, with total overall survival of 73 months from diagnosis.

PubMed CentralRead more →

Stage IVA lung cancer with small-cell and adenocarcinoma components: mixed response before infection halted treatment

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 <1%

Metastatic Site: bone (C2, T10, sacral vertebrae); malignant pleural…

The lung cancer showed mixed responses, with right-lung small-cell progression after chemotherapy/immunotherapy and later treatment interruption because of severe lung infection and respiratory failure.

PubMed CentralRead more →

Metastatic lung adenocarcinoma with HER2 V659E/amplification responding to trastuzumab deruxtecan

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial lung testing showed no EGFR/ALK/ROS1 and PD-L1 TPS 3%. Later biopsy found HER2 V659E plus HER2 amplification.

Metastatic Site: liver, bone, brain

As of September 2024, metastatic lung adenocarcinoma had a sustained partial response to trastuzumab deruxtecan after HER2 V659E mutation and HER2 amplification were identified.

PubMed CentralRead more →

Recurrent lung adenocarcinoma with bevacizumab-associated glomerular microangiopathy

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: No tumor molecular biomarkers reported. Kidney biopsy and complement/immune deposits supported bevacizumab-related kidney microangiopathy.

Metastatic Site: pleura

He was living with recurrent metastatic lung adenocarcinoma after pleural spread and had persistent renal dysfunction and severe proteinuria from bevacizumab-associated glomerular microangiopathy despite stopping bevacizumab.

PubMed CentralRead more →

Metastatic hormone receptor-positive breast cancer: palbociclib and fulvestrant during dialysis

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-negative; HER2 0 / HER2-negative; Ki-67 20.1%

Metastatic Site: lung, pleura, bone, right supraclavicular lymph node

As of August 2025, metastatic breast cancer had remained stable for 18 months on fulvestrant plus dialysis-adjusted palbociclib dosing, with hematologic toxicity managed through treatment interruptions, transfusion, and dose reduction.

PubMed CentralRead more →

Stage IIB HER2-positive apocrine breast carcinoma treated with chemotherapy, trastuzumab, radiation, and tamoxifen

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER 80%; PR 5%; HER2-positive by HercepTest and FISH; Ki-67 15%; AR testing not performed

At 7 months of follow-up, the patient remained in remission, with no locoregional recurrence or distant metastasis reported.

PubMed CentralRead more →

Stage IV Breast Cancer: Suzy's Survivor Story

Patient Info: Suzy, Female | Stage IV

Metastatic Site: Bone

As of July 2025, Suzy was living with de novo Stage IV bone-metastatic breast cancer and had achieved no evidence of active disease after starting targeted treatment in May 2023.

HER2-positive node-positive breast cancer: mastectomy and adjuvant TCbHP

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: HER2-positive breast cancer with ER/PR positivity, PD-L1 CPS 25

Adjuvant TCbHP was initiated after surgery, the first cycle was tolerated with supportive care, and regular monitoring was ongoing without evidence of distant recurrence or metastasis reported.

PubMed CentralRead more →

BRAF V600E stage IV lung adenocarcinoma with complete radiologic remission on dabrafenib-trametinib

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: BRAF lung cancer with PD-L1 TPS 95%, and TMB 6.3. TP53 and CHEK2 changes were also reported.

Metastatic Site: left adrenal gland, right adrenal gland,…

As of February 2024, she had ECOG performance status 0, no need for oxygen therapy, no radiologic evidence of active oncologic disease, no visible adrenal lesions, and only residual scarring at the primary lung site.

PubMed CentralRead more →